BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 38241363)

  • 21. Modulation of Early Mitotic Inhibitor 1 (EMI1) depletion on the sensitivity of PARP inhibitors in BRCA1 mutated triple-negative breast cancer cells.
    Moustafa D; Elwahed MRA; Elsaid HH; Parvin JD
    PLoS One; 2021; 16(1):e0235025. PubMed ID: 33412559
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DNA methyltransferase inhibitors induce a BRCAness phenotype that sensitizes NSCLC to PARP inhibitor and ionizing radiation.
    Abbotts R; Topper MJ; Biondi C; Fontaine D; Goswami R; Stojanovic L; Choi EY; McLaughlin L; Kogan AA; Xia L; Lapidus R; Mahmood J; Baylin SB; Rassool FV
    Proc Natl Acad Sci U S A; 2019 Nov; 116(45):22609-22618. PubMed ID: 31591209
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression patterns and prognostic relevance of subtype-specific transcription factors in surgically resected small-cell lung cancer: an international multicenter study.
    Megyesfalvi Z; Barany N; Lantos A; Valko Z; Pipek O; Lang C; Schwendenwein A; Oberndorfer F; Paku S; Ferencz B; Dezso K; Fillinger J; Lohinai Z; Moldvay J; Galffy G; Szeitz B; Rezeli M; Rivard C; Hirsch FR; Brcic L; Popper H; Kern I; Kovacevic M; Skarda J; Mittak M; Marko-Varga G; Bogos K; Renyi-Vamos F; Hoda MA; Klikovits T; Hoetzenecker K; Schelch K; Laszlo V; Dome B
    J Pathol; 2022 Aug; 257(5):674-686. PubMed ID: 35489038
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of Karyopherin β1-Mediated Nuclear Import Disrupts Oncogenic Lineage-Defining Transcription Factor Activity in Small Cell Lung Cancer.
    Kelenis DP; Rodarte KE; Kollipara RK; Pozo K; Choudhuri SP; Spainhower KB; Wait SJ; Stastny V; Oliver TG; Johnson JE
    Cancer Res; 2022 Sep; 82(17):3058-3073. PubMed ID: 35748745
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer.
    Chabanon RM; Muirhead G; Krastev DB; Adam J; Morel D; Garrido M; Lamb A; Hénon C; Dorvault N; Rouanne M; Marlow R; Bajrami I; Cardeñosa ML; Konde A; Besse B; Ashworth A; Pettitt SJ; Haider S; Marabelle A; Tutt AN; Soria JC; Lord CJ; Postel-Vinay S
    J Clin Invest; 2019 Mar; 129(3):1211-1228. PubMed ID: 30589644
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Loss of nuclear DNA ligase III reverts PARP inhibitor resistance in BRCA1/53BP1 double-deficient cells by exposing ssDNA gaps.
    Paes Dias M; Tripathi V; van der Heijden I; Cong K; Manolika EM; Bhin J; Gogola E; Galanos P; Annunziato S; Lieftink C; Andújar-Sánchez M; Chakrabarty S; Smith GCM; van de Ven M; Beijersbergen RL; Bartkova J; Rottenberg S; Cantor S; Bartek J; Ray Chaudhuri A; Jonkers J
    Mol Cell; 2021 Nov; 81(22):4692-4708.e9. PubMed ID: 34555355
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer.
    Lok BH; Gardner EE; Schneeberger VE; Ni A; Desmeules P; Rekhtman N; de Stanchina E; Teicher BA; Riaz N; Powell SN; Poirier JT; Rudin CM
    Clin Cancer Res; 2017 Jan; 23(2):523-535. PubMed ID: 27440269
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Poly(ADP-Ribose) Polymerase Inhibition in Small Cell Lung Cancer: A Review.
    Guo MZ; Marrone KA; Spira A; Scott SC
    Cancer J; 2021 Nov-Dec 01; 27(6):476-481. PubMed ID: 34904810
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer.
    Sen T; Rodriguez BL; Chen L; Corte CMD; Morikawa N; Fujimoto J; Cristea S; Nguyen T; Diao L; Li L; Fan Y; Yang Y; Wang J; Glisson BS; Wistuba II; Sage J; Heymach JV; Gibbons DL; Byers LA
    Cancer Discov; 2019 May; 9(5):646-661. PubMed ID: 30777870
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic targeting of BAP1/ASXL3 sub-complex in ASCL1-dependent small cell lung cancer.
    Tsuboyama N; Wang R; Szczepanski AP; Chen H; Zhao Z; Shi L; Wang L
    Oncogene; 2022 Apr; 41(15):2152-2162. PubMed ID: 35194152
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PARP inhibitors: Synthetic lethality in the clinic.
    Lord CJ; Ashworth A
    Science; 2017 Mar; 355(6330):1152-1158. PubMed ID: 28302823
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sensitivity of Small Cell Lung Cancer to BET Inhibition Is Mediated by Regulation of ASCL1 Gene Expression.
    Lenhart R; Kirov S; Desilva H; Cao J; Lei M; Johnston K; Peterson R; Schweizer L; Purandare A; Ross-Macdonald P; Fairchild C; Wong T; Wee S
    Mol Cancer Ther; 2015 Oct; 14(10):2167-74. PubMed ID: 26253517
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2
    Liu L; Cai S; Han C; Banerjee A; Wu D; Cui T; Xie G; Zhang J; Zhang X; McLaughlin E; Yin M; Backes FJ; Chakravarti A; Zheng Y; Wang QE
    Mol Cancer Ther; 2020 Jan; 19(1):199-210. PubMed ID: 31534014
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multi-omics analysis reveals distinct non-reversion mechanisms of PARPi resistance in BRCA1- versus BRCA2-deficient mammary tumors.
    Bhin J; Paes Dias M; Gogola E; Rolfs F; Piersma SR; de Bruijn R; de Ruiter JR; van den Broek B; Duarte AA; Sol W; van der Heijden I; Andronikou C; Kaiponen TS; Bakker L; Lieftink C; Morris B; Beijersbergen RL; van de Ven M; Jimenez CR; Wessels LFA; Rottenberg S; Jonkers J
    Cell Rep; 2023 May; 42(5):112538. PubMed ID: 37209095
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer.
    Chiappa M; Guffanti F; Bertoni F; Colombo I; Damia G
    Drug Resist Updat; 2021 Mar; 55():100744. PubMed ID: 33551306
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DNA Damage Repair and the Emerging Role of Poly(ADP-ribose) Polymerase Inhibition in Cancer Therapeutics.
    Rabenau K; Hofstatter E
    Clin Ther; 2016 Jul; 38(7):1577-88. PubMed ID: 27368114
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer.
    Ma L; Bian X; Lin W
    J Exp Clin Cancer Res; 2020 Oct; 39(1):219. PubMed ID: 33069237
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Darinaparsin (ZIO-101) enhances the sensitivity of small-cell lung cancer to PARP inhibitors.
    Cao GZ; Ma LY; Zhang ZH; Wang XL; Hua JH; Zhang JH; Lv Y; Zhang SB; Ou J; Lin WC
    Acta Pharmacol Sin; 2023 Apr; 44(4):841-852. PubMed ID: 36253561
    [TBL] [Abstract][Full Text] [Related]  

  • 39. p66ShcA potentiates the cytotoxic response of triple-negative breast cancers to PARP inhibitors.
    Cañedo EC; Totten S; Ahn R; Savage P; MacNeil D; Hudson J; Autexier C; Deblois G; Park M; Witcher M; Ursini-Siegel J
    JCI Insight; 2021 Feb; 6(4):. PubMed ID: 33470989
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug-gene Interaction Screens Coupled to Tumor Data Analyses Identify the Most Clinically Relevant Cancer Vulnerabilities Driving Sensitivity to PARP Inhibition.
    Jamal K; Galbiati A; Armenia J; Illuzzi G; Hall J; Bentouati S; Barrell D; Ahdesmäki M; ; O'Connor MJ; Leo E; Forment JV
    Cancer Res Commun; 2022 Oct; 2(10):1244-1254. PubMed ID: 36969741
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.